Biomedical subjects

Hae Won Kim

Publications and source records attributed to Hae Won Kim.

8 recordsLinked to original sources

PubMed2006

Toward 21st century blood component replacement therapeutics: artificial oxygen carriers, platelet substitutes, recombinant clotting factors, and others.

In this brief overview, recent progress and current status of blood substitute research and development is summarized. Current blood substitute development efforts are focused on red blood cell substitutes but substitutes for platelets and other blood components are also in progress. Red cell substitutes currently in various stages of development are semi-synthetic or synthetic oxygen carriers that include "stealth" or "masked" red cells, hemoglobin-based oxygen carriers and perfluorocarbon-based oxygen carriers. Artificial platelets (or platelet substitutes) are in early stages of development and include human platelet fragments or particles of synthetic/semi-synthetic materials or recombinant human serum albumin coupled with platelet surface receptor fragments. Of note, some recombinant clotting factors (Factors VII, VIII, IX) have already been successfully developed and licensed for treatment of hemophilia. In addition, some future approaches and prospects of blood component replacement therapeutics are discussed.

Blood Coagulation Factors↗

PubMed2006

Intake of dietary soy isoflavones in relation to perimenstrual symptoms of Korean women living in the USA.

This study was conducted to identify the potential relationship between the dietary intake level of soy isoflavones and perimenstrual symptomatology. The research design was a cross-sectional study. The sample was made up of 84 Korean women living in the USA, aged 28-40 years. The Moos Menstrual Distress Questionnaire (MDQ) and the Food Frequency Questionnaire were used as measurement tools. The soy isoflavone intake was significantly correlated with MDQ scores in the menstrual phase. In conclusion, the beneficial effect of dietary soy isoflavones on certain menstrual symptoms was established, suggesting that soy isoflavones could be one of the dietary factors related to the complexity of premenstrual syndrome (PMS). The positive effect of soy isoflavones on PMS warrants further study.

Adult↗

PubMed2006

[The effects of a PMS nutritional education program for college students].

PURPOSE: This study was conducted to identify the effects of a PMS nutritional education program for college nursing students. METHOD: Subjects consisted of nursing students(experimental group: 29, control group: 27). The experimental group participated in a PMS nutritional education program for 8 weeks (including group and individual involvement). Data was collected before and after the education, and measurement tools were premenstrual symptoms, PMS knowledge, and self health behavior. RESULTS: After the intervention, the experimental group showed a significant increase in PMS knowledge(Z=6.32, p=.000) and self health behavior(t=3.00, p=.004) compared to the control group. After the intervention the experimental group showed a significant increase in PMS knowledge(Z=-4.64, p=.000) and self health behavior(t=-3.04, p=.005) than before the intervention. CONCLUSIONS: These results suggest that the short term effects of a PMS nutritional education program for nursing students was proven useful and the program should be applied to PMS nutrition education for PMS clients as well as health professionals.

Adult↗

PubMed2004

Role of glutathione in the adaptive tolerance to H2O2.

Endogenous antioxidant defense systems are enhanced by various physiological stimuli including sublethal oxidative challenges, which induce tolerance to subsequent lethal oxidative injuries. We sought to evaluate the contributions of catalase and the glutathione system to the adaptive tolerance to H2O2. For this purpose, H9c2 cells were stimulated with 100 microM H2O2, which was the maximal dose at which no significant acute cell damage was observed. Twenty-four hours after stimulation, control and pretreated cells were challenged with a lethal concentration of H2O2 (300 microM). Compared with the control cells, pretreated cells were significantly tolerant of H2O2, with reduced cell lysis and improved survival rate. In pretreated cells, glutathione content increased to 48.20 +/- 6.38 nmol/mg protein versus 27.59 +/- 2.55 nmol/mg protein in control cells, and catalase activity also increased to 30.82 +/- 2.64 versus 15.46 +/- 1.29 units/mg protein in control cells, whereas glutathione peroxidase activity was not affected. Increased glutathione content was attributed to increased gamma-glutamylcysteine synthetase activity, which is known as the rate-limiting enzyme of glutathione synthesis. To elucidate the relative contribution of the glutathione system and catalase to tolerance of H2O2, control and pretreated cells were incubated with specific inhibitors of gamma-glutamyl cysteine synthetase (L-buthionine sulfoximine) or catalase (3-amino-1,2,4-triazole), and challenged with H2O2. Cytoprotection by the low-dose H2O2 pretreatment was almost completely abolished by L-buthionine sulfoximine, while it was preserved after 3-amino-1,2,4-triazole treatment. From these results, it is concluded that both the glutathione system and catalase can be enhanced by H2O2 stimulation, but increased glutathione content rather than catalase activity was operative in the tolerance of lethal oxidative stress.

Amitrole↗

PubMed2004

Hemoglobin-based oxygen carriers.

Transfusable fluids that may be used as alternatives to red blood cell transfusion offer the promise of preserving tissue perfusion and minimizing hypoxic cellular damage, and this promise may soon be fulfilled. Clinical testing of hemoglobin-based oxygen carriers has faced and met challenges involving molecular design, safety, efficacy, and regulatory requirements. Three leading candidates have emerged: two human (PolyHeme and HemoLink) and one bovine-based hemoglobin solution (Hemopure). Because a survival benefit has been difficult to demonstrate, avoidance of allogeneic transfusion has been adopted as the standard efficacy end-point for these agents. An update on clinical trial status is provided, and the potential utility of hemoglobin-based oxygen carriers in surgery combined with intraoperative autologous donation is discussed.

Animals↗

PubMed2004

Civilian uses of hemoglobin-based oxygen carriers.

This article briefly discusses a few key issues related to transfusion, the concept of hemoglobin-based red blood cell substitutes (HBOCs), and some parameters useful in evaluating the current properties of solutions. Potential uses of HBOCs in civilian applications are identified and listed. Use of HBOCs as a hemodiluent for intraoperative autologous blood donation (IAD) is a particular application that has relevance in many surgical settings and this is discussed in some detail. Data from a Phase III clinical trial is presented to show the potential for avoiding the use of allogeneic blood and blood products in a clinical model of large volume red cell use. Extrapolation to a general use model, primarily based in the potential for surgery, will be noted. Some general parametric values of HBOCs are presented. These values are by no means considered optimal for all HBOCs and are subject to exploration, fine tuning, correction, or even rejection.

Blood Substitutes↗

PubMed2004

Artificial oxygen carriers as red blood cell substitutes: a selected review and current status.

Two distinct approaches are being explored in red blood cell substitute (RCS) development: hemoglobin-based oxygen carriers (HBOCs) and perfluorocarbon-based oxygen carriers (PFBOCs). HBOCs are based on intra- and/or intermolecularly "engineered" human or animal hemoglobins (Hbs), optimized for O2 delivery and longer intravascular circulation. Some are currently being evaluated in Phase II/III clinical studies. PFBOCs are aqueous emulsions of perfluorocarbon derivatives that dissolve relatively large amounts of O2. A PFBOC based on a 60% (wt/vol) emulsion of perfluorooctyl bromide has been evaluated in Phase II/III clinical trials. Although current PFBOC products generally require patients to breathe O2 enriched air, they render certain advantages since they are totally synthetic. This article provides a short review of the basic principles, approaches, and current status of RCS development. Results of preclinical and clinical studies including recent Phase II/III clinical studies are discussed.

Blood Substitutes↗

PubMed2003

Effects of methyl methacrylate on Ca2+ uptake of cardiac sarcoplasmic reticulum.

In isolated cardiac sarcoplasmic reticulum (SR) vesicles, methyl methacrylate (2.5-100mM) directly inhibited initial rates of Ca2+ uptake as well as the maximal uptake. Inhibition of SR Ca2+ uptake by methyl methacrylate was concentration-dependent, and the highest concentration of methyl methacrylate (100mM) almost completely inhibited the SR Ca2+ uptake. EC(50) of methyl methacrylate in percent inhibition of SR Ca2+ uptake was 16.1, 31.9, and 53.4mM at pCa 7.0, 6.6, and 6.0, respectively. At low Ca2+ concentrations (0.1-1 microM), SR vesicles treated with 20mM methyl methacrylate showed the decreased Ca2+ uptake rates. However, further increase of Ca2+ concentration to pCa 5.5 abolished the inhibitory effect of methyl methacrylate on SR Ca2+ uptake, showing no difference between the control and the methyl methacrylate-treated SR vesicles. From these results we could conclude that methyl methacrylate exerts a direct inhibition of cardiac SR Ca2+ uptake. This mechanism, at least in part, might contribute to the profound hypotension induced by methyl methacrylate. Supplementation of calcium ion appears to reduce the methyl methacrylate-induced cardiovascular disturbances efficiently.

Animals↗